ACH
CSTL icon

ArrowMark Colorado Holdings’s Castle Biosciences CSTL Stock Holding History

ArrowMark Colorado Holdings’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-203,300
Closed -$9.12M – 333
2022
Q1 		$9.12M Buy
203,300
+12,075
+6% +$499K 0.08% 199
2021
Q4 		$8.2M Buy
191,225
+139,992
+273% +$7.32M 0.07% 214
2021
Q3 		$3.41M Buy
51,233
+389
+0.8% +$27.4K 0.03% 264
2021
Q2 		$3.73M Sell
50,844
-9,834
-16% -$650K 0.03% 253
2021
Q1 		$4.15M Sell
60,678
-5,106
-8% -$384K 0.03% 246
2020
Q4 		$4.42M Sell
65,784
-22,435
-25% -$1.22M 0.03% 237
2020
Q3 		$4.54M Sell
88,219
-5,756
-6% -$256K 0.04% 223
2020
Q2 		$3.54M Buy
93,975
+5,452
+6% +$186K 0.04% 206
2020
Q1 		$2.64M Buy
88,523
+9,868
+13% +$298K 0.03% 203
2019
Q4 		$2.7M Buy
78,655
+8,655
+12% +$212K 0.02% 236
2019
Q3 		$1.27M Buy
+70,000
New +$1.55M 0.01% 240

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

ArrowMark Colorado Holdings's CSTL Position: Q2 2022 in Review

ArrowMark Colorado Holdings sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 203,300 shares — an estimated $9.12M sold.

ArrowMark Colorado Holdings first reported a position in CSTL in Q3 2019 and held it in 11 quarters. The position peaked at $9.12M in Q1 2022. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

  • ArrowMark Colorado Holdings reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 203,300 Castle Biosciences shares in Q2 2022, an estimated $9.12M.
  • ArrowMark Colorado Holdings first reported a position in Castle Biosciences in Q3 2019 and held it in 11 quarters.
  • ArrowMark Colorado Holdings's Castle Biosciences position peaked at $9.12M in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.